Blog

Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Conditions:   Acute Respiratory Distress Syndrome;   COVID-19
Intervention:   Procedure: Stellate Ganglion Block
Sponsor:   West Virginia University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 28, 2020 / by / in
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Condition:   Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Intervention:   Biological: AUTO1
Sponsor:   Autolus Limited
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 28, 2020 / by / in
Unilateral TAP Block for Laparoscopic Gastric Sleeve Surgery
Conditions:   Laparoscopic Sleeve Gastrectomy;   Subcostal Transversus Abdominis Plane Block
Interventions:   Drug: Saline;   Drug: Bupivacaine
Sponsor:   Icahn School of Medicine at Mount Sinai
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 27, 2020 / by / in
Measuring Cell Free Tumor DNA (cfDNA) Levels in Blood and Cerebrospinal Fluid Before, During, and After First-Line Chemotherapy for Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma (PCNSL)
Intervention:   Drug: Nivolumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 27, 2020 / by / in
Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging
Condition:   Esophageal Cancer
Interventions:   Other: Injection of indocyanine green (ICG)dye;   Device: Near-Infrared Image-Guided;   Procedure: Sentinel Lymph Node (SNL) mapping
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 23, 2020 / by / in
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Conditions:   Gastric Neuroendocrine Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Pancreatic Neuroendocrine Carcinoma
Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 22, 2020 / by / in
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Conditions:   GastroEsophageal Cancer;   Gastric Cancer
Interventions:   Drug: Lenvatinib;   Drug: Pembrolizumab
Sponsor:   NYU Langone Health
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 22, 2020 / by / in
Assessing the Sensitivity of “SureTouch™” in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography
Condition:   Breast Cancer
Intervention:   Device: SureTouch
Sponsors:   Rebecca Kaltman, MD;   Sure, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 22, 2020 / by / in
RASopathy Biorepository
Conditions:   RAS Mutation;   Neurofibromatosis 1;   Noonan Syndrome;   Noonan Syndrome With Multiple Lentigines;   Noonan Neurofibromatosis Syndrome;   Cardiofaciocutaneous Syndrome;   Costello Syndrome;   Legius Syndrome;   Smith-Kingsmore Syndrome;   Mammilian Target of Rapamycin (MTOR) Gene Mutation;   GATOR-1;   SYNGAP1-Related Intellectual Disability;   DLG4;   MAPK1 Gene Mutation
Intervention:  
Sponsor:   Children’s Hospital Medical Center, Cincinnati
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 21, 2020 / by / in
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Condition:   HER2-positive Breast Cancer
Intervention:   Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
Sponsor:   Genentech, Inc.
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 21, 2020 / by / in